1 results
Approved WMORecruiting
This study has been transitioned to CTIS with ID 2024-518036-36-01 check the CTIS register for the current data. To prove that the RECAP test has the potential of selecting patients who are sensitive to treatment with the PARP inhibitor talazoparib…